Dishman Carbogen Amcis Limited — Investor Meet, 20-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Dishman Carbogen Amcis Limited reported a strong revenue of INR 789 crores for Q2, marking a substantial increase from INR 586 crores in the same quarter last year. EBITDA reached an impressive INR 148 crores, representing one of the highest margins at approximately 18.7%. The profit before tax was INR 42 crores, indicating a significant sequential growth from Q1, where high commercial revenues boosted financial performance despite challenges in specific product lines, like cholesterol and vitamin D analogues, which saw a revenue decline to INR 55 crores from INR 86 crores year-over-year.

2. **Future Outlook and Growth Drivers**: Management expressed confidence in capturing new business, particularly with the expectation of increased investments post-U.S. elections. The focus will be on ramping up operations at the newly validated French facility and expanding collaborations between Carbogen Amcis and Dishman in India. The targeted revenue for Carbogen Amcis for FY '25 is CHF 255 million, bolstered by a stable commercial pipeline.

3. **Order Book and Operational Updates**: The order book for Carbogen Amcis has decreased to CHF 110 million, attributed to delays in capturing new projects. However, management is optimistic about recapturing this ground soon, especially with recent contract wins contributing positively.

4. **Analyst Q&A Insights**: Analysts raised concerns about revenue growth projections and the competitive landscape. Management reassured that the revenue expectations are on track, supported by robust commercial growth. Supply chain challenges and cost pressures were discussed, with positive developments anticipated shortly, particularly regarding lower raw material prices expected from Q4.

5. **Market or Regulatory Updates**: The introduction of the Biosecure Act in the U.S. could lead to advantageous inquiries for Indian manufacturers, with management indicating an increase in inquiries driven by this act, although growth has been modest (10-15%).

6. **Strategic Focus Areas**: There is a clear focus on innovation and efficiency, as management expects digital transformation and reorganization initiatives to yield operational benefits in the upcoming year. The anticipating shift from high operational costs to profitability is key to strategy moving forward.

7. **Investor Insight**: The financial health appears strong, with a good trajectory of growth potential, especially with rising revenues in CRAMS and an optimistic outlook for EBITDA improvement. Given the momentum and strategic positioning, this aligns with a 'buy' position, contingent on sustained market recovery and successful capture of new projects amidst increasing competition.